Gregory Bacon


Greg is an experienced IP and regulatory lawyer with a particular focus on the life sciences sector.

His extensive scientific background gives him a valuable understanding of technical issues that can underlie IP and regulatory matters, particularly in the life sciences field. He has advised and represented clients on small molecule pharmaceuticals, biologics (originators and biosimilars), medical devices (traditional and software), as well as in the chemicals, technology, shipping and online publishing sectors.

Greg’s particular focus is on patent litigation. He has extensive experience of acting before both the English High Court and Court of Appeal. In addition, Greg has extensive experience of strategic multinational litigation in multiple jurisdictions, including at the EPO, through global pharmaceutical product coordination projects for many clients. He also provides regulatory advice on the legislative frameworks governing pharmaceuticals and medical devices, both at EU and national level.

Example cases:

  • Novartis v Focus, Actavis & Teva – Patents Court and Court of Appeal patent litigation concerning transdermal dosage regime patent for rivastigmine (Exelon®), including global coordination of parallel litigation and EPO opposition
  • Celltrion v Biogen, Roche & Genentech – clearing the way revocation action in the Patents Court in relation to biosimilar rituximab product (MabThera®)
  • Merck Serono v AbbVie – clearing the way revocation action in the Patents Court in relation to biosimilar adalimumab product (Humira®)
  • ConvaTec v Smith & Nephew – long-running case in the Patents Court and Court of Appeal concerning patents and claims to misuse of confidential information in relation to gel-forming wound dressings (Durafiber®), and subsequent damages claim under a cross-undertaking
  • Allergan v Ipsen – patent litigation in the Patents Court on second medical use patents to botulinum toxin (Dysport®)
  • Servier v National Institute of Health and Clinical Excellence (NICE) – successful judicial review of NICE decision not to recommend a client’s osteoporosis treatment (Protelos®).

Greg has spent time on secondment to the IP litigation department of a leading IP law firm in the Netherlands as well as the UK legal department of a leading global healthcare IT company, working on non-contentious IP/IT, regulatory and commercial matters.

Greg is a regular contributor to the monthly EPO reports which Bristows produce for the CIPA Journal and writes on UK cases for a number of IP blogs. He is also the editor of our On the Pulse life sciences microsite and one of the editors of our Biotech Review publication which explores key issues and developments in the biotech space, and co-authored the UK chapter of the AIPLA’s International Patent Litigation guide.


  • BA (Hons) Natural Sciences (Neuroscience), University of Cambridge
  • DPhil Neuroscience, University of Oxford
  • Diploma in Intellectual Property Law and Practice, University of Oxford
  • Qualified 2007
  • Partner 2017

What others say

"creative thinker" Legal 500 2020

Recommended For

Who's Who Legal 2020

Life Sciences: Patent Litigation
Who's Who Legal 2020

Pharmaceutical and Biotechnology
Legal 500 2020

Intellectual Property
Legal 500 2019

Related Articles